Research programme: tuberculosis therapeutics - Astellas Pharma/Global Alliance for TB Drug Development
Alternative Names: Research programme: anti-tuberculosis therapeutics - Astellas Pharma/TB AllianceLatest Information Update: 28 Nov 2022
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Global Alliance for TB Drug Development
- Class Antituberculars
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for research development in Tuberculosis in Japan
- 28 Nov 2022 No recent reports of development identified for research development in Tuberculosis in USA
- 18 Oct 2017 Astellas Pharma and the Global Alliance for TB Drug Development agree to co-promote and co-develop tuberculosis therapeutics in Japan and USA for Tuberculosis